




PHARMACEUTICAL 2021

BIOXYTRAN INC
Rank 389 of 402





PHARMACEUTICAL 2021

BIOXYTRAN INC Rank 389 of 402

The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 207% points. The greatest weakness of BIOXYTRAN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 289% points.

The company's Economic Capital Ratio, given in the ranking table, is -449%, being 496% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	316
Cost of Goods Sold	0
Intangible Assets	10
Liabilities, Current	2,268
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	248
Other Liabilities	0
Other Net Income	-1,212
Other Revenues	0
Property and Equipment	0
Research and Development	545
Selling, General and Administrative Expense	476

Output Variable	Value in 1000 USD
Assets	326
Liabilities	2,268
Expenses	1,269
Revenues	0
Stockholders Equity	-1,941
Net Income	-2,481
Comprehensive Net Income	-2,481
Economic Capital Ratio	-449%